Autobahn Therapeutics, a biotechnology company leveraging its brain-targeting chemistry platform and strategies driven by clinical precedence and validated biology to develop restorative treatments for people affected by central nervous system (CNS) disorders, today announced that Kevin Finney, President and Chief Executive Officer, will present at the following upcoming investor conferences:

• Jefferies Inaugural CNS & Neuro Summit: Presentation on Wednesday, October 11, 2023, at 10:00 a.m. ET.
• BMO Life Sciences Private Company Showcase: Presentation on Thursday, October 12, 2023, at 9:45 a.m. ET.

About Autobahn Therapeutics

Autobahn Therapeutics is a biotechnology company developing a portfolio of neuropsychiatric and neurodegenerative clinical candidates leveraging its brain-targeting chemistry platform. Autobahn aims to unlock new therapeutic opportunities through precision tuning of CNS exposure, pursuing validated clinical and biologic targets, and guiding development with biomarkers. The company’s pipeline is led by ABX-002, a thyroid hormone receptor beta agonist, being developed as a potential adjunctive treatment for people with major depressive disorder (MDD), including those who have had an inadequate response to their antidepressant. Autobahn Therapeutics is based in San Diego. For more information, visit www.autobahntx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231004666977/en/